Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Equity Ratio (2016 - 2025)

Amicus Therapeutics' Equity Ratio history spans 16 years, with the latest figure at 0.29 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 16.8% year-over-year to 0.29, compared with a TTM value of 0.29 through Dec 2025, up 16.8%, and an annual FY2025 reading of 0.29, up 16.8% over the prior year.
  • Equity Ratio for Q4 2025 was 0.29 at Amicus Therapeutics, up from 0.27 in the prior quarter.
  • The five-year high for Equity Ratio was 0.39 in Q3 2021, with the low at 0.15 in Q1 2023.
  • Average Equity Ratio over 5 years is 0.24, with a median of 0.24 recorded in 2024.
  • Year-over-year, Equity Ratio tumbled 55.67% in 2022 and then surged 41.72% in 2025.
  • Tracing FOLD's Equity Ratio over 5 years: stood at 0.34 in 2021, then tumbled by 49.96% to 0.17 in 2022, then rose by 21.18% to 0.21 in 2023, then rose by 20.04% to 0.25 in 2024, then increased by 16.8% to 0.29 in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Equity Ratio are 0.29 (Q4 2025), 0.27 (Q3 2025), and 0.25 (Q2 2025).